Company Description
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 680 |
| CEO | Richard Adcock |
Contact Details
Address: 3530 John Hopkins Court San Diego, California 92121 United States | |
| Phone | 844 696 5235 |
| Website | immunitybio.com |
Stock Details
| Ticker Symbol | IBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326110 |
| CUSIP Number | 45256X103 |
| ISIN Number | US45256X1037 |
| Employer ID | 43-1979754 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Gerald Adcock | President, Chief Executive Officer and Director |
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. | Executive Chairman of the Board and Global Chief Scientific and Medical Officer |
| David C. Sachs | Chief Financial Officer |
| Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer and Director |
| Regan J. Lauer | Chief Accounting Officer |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer |
| Jason R. Liljestrom J.D. | General Counsel and Corporate Secretary |
| Sarah Singleton | Chief Communications Officer and Head of Patient Advocacy |
| Dr. Leonard S. Sender M.D. | Chief Medical Officer of Liquid Tumors and Cell Therapy |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| May 5, 2025 | 8-K | Current Report |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 8, 2025 | 424B5 | Filing |
| Apr 8, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |